Table 1.
Lipids, Inflammatory Parameters, and Cardiac Biomarkers
| Baseline Placebo (n=21) |
Baseline Atorvastatin (n=19) |
Between Group P-value |
12-month Placebo (n=20) |
12-month Atorvastatin (n=17) |
Within Group (Placebo) P-value |
Within Group (Atorvastatin) P-value |
Change Placebo (n=20) |
Change Atorvastatin (n=17) |
Between Group P-value |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Lipids | ||||||||||
|
| ||||||||||
| Total cholesterol (mg/dL) | 192 ± 27 | 199 ± 38 | 0.52 | 198 ± 29 | 153 ± 29 | 0.30 | <0.0001 | 5 ± 20 | −47 ± 23 | <0.0001 |
| HDL-Cholesterol (mg/dL) | 51 ± 15 | 52 ± 19 | 0.84 | 49 ± 15 | 55 ± 17 | 0.54 | 0.70 | −2 ± 11 | 1 ± 10 | 0.48 |
| Direct LDL-Cholesterol (mg/dL) | 125 ± 32 | 124 ± 37 | 0.93 | 137 ± 30 | 86 ± 30 | 0.03 | <0.0001 | 11 ± 21 | −38 ± 29 | <0.0001 |
| Triglycerides (mg/dL) | 113 (92 to 136) | 120 (97 to 204) | 0.39 | 117 (86 to 176) | 110 (81 to 134) | 0.93 | 0.49 | 8 (−41 to 34) | −9 (−41 to 39) | 0.64 |
| Oxidized LDL (U/L) | 63.5 ± 13.1 (n=21) | 62.2 ± 15.9 (n=18) | 0.78 | 67.7 ± 19.2 (n=21)* | 47.2 ± 11.3 (n=18)* | 0.24 | <0.0001 | 4.2 ± 15.8 (n=21)* | −14.9 ± 10.1 (n=18)* | <0.0001 |
|
| ||||||||||
| Inflammatory Parameters | (n=21) | (n=19) | ||||||||
|
| ||||||||||
| C-reactive protein (mg/L) | 1.1 (0.4 to 2.4) | 0.8 (0.3 to 1.9) | 0.36 | 1.5 (0.5 to 3.2) | 0.5 (0.3 to 1.2) | 0.26 | 0.27 | 0.2 (−0.1 to 1.5) | −0.1 (−1.1 to 0.2) | 0.07 |
| Interleukin-6 (ng/L) | 0.8 (0.5 to 1.2) | 0.6 (0.4 to 1.6) | 0.75 | 1.0 (0.5 to 1.8) | 0.8 (0.6 to 1.1) | 0.44 | 0.93 | 0.1 (−0.2 to 0.4) | 0.2 (−0.8 to 0.3) | 0.77 |
| sCD14 (ng/mL) | 1953 (350 to 2400) | 2100 (1088 to 2552) | 0.48 | 1848 (475 to 2652) | 1064 (509 to 2466) | 0.31 | 0.26 | 125 (−238 to 495) | −162 (−780 to 201) | 0.15 |
|
| ||||||||||
| Cardiac Biomarkers | (n=20) | (n=17) | ||||||||
|
| ||||||||||
| Galectin-3 (ng/ml) | 11.8 (10.3 to 15.2) (n=19) | 13.2 (10.4 to 15.4) | 0.63 | 13.9 (10.2 to 15.3) | 12.5 (11.0 to 16.9) | 0.26 | 0.43 | 0.5 (−1.1 to 1.8) (n=19) | 0.2 (−1.5 to 3.2) | 0.97 |
| sST2 (ng/ml) | 24.7 (20.4 to 30.9) | 27.7 (20.4 to 36.2) | 0.49 | 26.9 (21.4 to 31.1) | 27.0 (20.0 to 31.8) | 0.02 | 0.55 | 1.2 (0.6 to 4.7) | −0.3 (−4.2 to 2.1) | 0.04 |
| GDF-15 (pg/ml) | 2221 ± 2458 (n=19) | 1357 ± 836 (n=16) | 0.16 | 2482 ± 2372 (n=19) | 1339 ± 602 (n=16) | 0.04 | 0.86 | 262 ± 507 (n=19) | −19 ± 425 (n=16) | 0.08 |
Data reported as mean ± standard deviation or median (IQR).
*
Serum from last visit prior to study discontinuation used for 12-month oxidized LDL
Within group changes assessed by paired t-test for normally distributed variables or by Wilcoxon signed rank test as nonparametric version of paired t-test for non-normally distributed variables. Between group differences assessed by Student’s t-test for normally distributed variables or by Wilcoxon rank sum test for non-normally distributed variables.